Hemophilia A, B prophylaxis therapy Hympavzi may soon be …
Oct 25, 2024 · Developer Pfizer has tagged Hympavzi with a wholesale acquisition cost of $795,600 per year, which compares to the “pricing for prophylactic treatments for hemophilia A …
Giroctocogene fitelparvovec prevents Hem A bleeds: New trial data
Dec 13, 2024 · These new data add to top-line findings from earlier this year, which showed that bleed rates among participants in the Phase 3 study (NCT04370054) were significantly lower …
Altuviiio shows benefit in preventing bleeds over Hemlibra: Analysis
Dec 17, 2024 · Its own approvals were supported by data from the HAVEN clinical trial program, including the Phase 3 HAVEN 3 trial (NCT02847637), which found the therapy significantly …
Centessa discontinues development of SerpinPC for hemophilia
Nov 15, 2024 · The company was also conducting a long-term open-label extension study called PRESent-6 (NCT06568302) to evaluate the safety and efficacy of SerpinPC for up to 25 …
Mim8 for hemophilia – Hemophilia News Today
Jul 24, 2024 · Mim8 in hemophilia clinical trials. Early clinical trials — 4882 (NCT05127473) and FRONTIER 1 (NCT04204408) — demonstrated that Mim8 was generally safe and well …
Concizumab reduces bleeding in patients without inhibitors
Nov 29, 2024 · That’s according to data from explorer8 (NCT04082429), an ongoing Phase 3 clinical study in which Novo Nordisk’s concizumab, delivered daily under the skin for at least …
Hemophilia bypassing agent Sevenfact lowers bleeds in patients...
Oct 18, 2024 · The bypassing agent also was administered where patients showed a poor response to NovoSeven RT (eptacog alfa), an approved bypassing agent marketed by Novo …
FDA approves marstacimab, now Hympavzi, for hemophilia
Oct 11, 2024 · Hympavzi approved for adults and children, ages 12 and older. Hemophilia is a rare disease caused by a missing or faulty clotting factor — a protein that helps the blood to …
Roctavian effective for hemophilia A over 7 years, per trial update
Feb 7, 2024 · That’s according to an update on a Phase 1/2 clinical trial (NCT02576795), launched in the U.K. in 2015, that’s testing the safety and efficacy of increasing doses of the …
IND-enabling studies for hemophilia A gene-editing therapy to …
Nov 19, 2024 · This approach should lead to a sustained increase in FVIII activity, normalizing blood clotting and preventing bleeds with hemophilia A. In a preclinical study, three nonhuman …